An Interpretable Classification Method for Predicting Drug Resistance in M. Tuberculosis by Zabeti, Hooman et al.
An Interpretable Classification Method for
Predicting Drug Resistance in M. Tuberculosis
Hooman Zabeti
School of Computing Science, Simon Fraser University, Burnaby, Canada
hooman_zabeti@sfu.ca
Nick Dexter
Department of Mathematics, Simon Fraser University, Burnaby, Canada
Amir Hosein Safari
School of Computing Science, Simon Fraser University, Burnaby, Canada
Nafiseh Sedaghat
School of Computing Science, Simon Fraser University, Burnaby, Canada
Maxwell Libbrecht
School of Computing Science, Simon Fraser University, Burnaby, Canada
Leonid Chindelevitch
School of Computing Science, Simon Fraser University, Burnaby, Canada
Abstract
Motivation: The prediction of drug resistance and the identification of its mechanisms in bacteria
such as Mycobacterium tuberculosis, the etiological agent of tuberculosis, is a challenging problem.
Modern methods based on testing against a catalogue of previously identified mutations often yield
poor predictive performance. On the other hand, machine learning techniques have demonstrated
high predictive accuracy, but many of them lack interpretability to aid in identifying specific
mutations which lead to resistance. We propose a novel technique, inspired by the group testing
problem and Boolean compressed sensing, which yields highly accurate predictions and interpretable
results at the same time.
Results: We develop a modified version of the Boolean compressed sensing problem for identifying
drug resistance, and implement its formulation as an integer linear program. This allows us to
characterize the predictive accuracy of the technique and select an appropriate metric to optimize.
A simple adaptation of the problem also allows us to quantify the sensitivity-specificity trade-off of
our model under different regimes. We test the predictive accuracy of our approach on a variety
of commonly used antibiotics in treating tuberculosis and find that it has accuracy comparable to
that of standard machine learning models and points to several genes with previously identified
association to drug resistance.
2012 ACM Subject Classification Applied computing; Applied computing → Bioinformatics; Ap-
plied computing → Molecular sequence analysis
Keywords and phrases Drug resistance, whole-genome sequencing, interpretable machine learning,
integer linear programming, rule-based learning
Digital Object Identifier 10.4230/LIPIcs.WABI.2020.2
Supplementary Material https://github.com/hoomanzabeti/TB_Resistance_RuleBased
Classifier
Funding This project was funded by the Genome Canada grant BAC283. LC acknowledges additional
funding from the CANSSI CRT and NSERC Discovery.
Acknowledgements The authors would like to thank Dr. Cedric Chauve, Dr. Ben Adcock and
Matthew Nguyen for helpful discussions.
© Hooman Zabeti, Nick Dexter, Amir Hosein Safari, Nafiseh Sedaghat, Maxwell Libbrecht, and
Leonid Chindelevitch;
licensed under Creative Commons License CC-BY
20th International Workshop on Algorithms in Bioinformatics (WABI 2020).
Editors: Carl Kingsford and Nadia Pisanti; Article No. 2; pp. 2:1–2:18
Leibniz International Proceedings in Informatics
Schloss Dagstuhl – Leibniz-Zentrum für Informatik, Dagstuhl Publishing, Germany
2:2 An Interpretable Classification Method for Drug Resistance
1 Introduction
Drug resistance is the phenomenon by which an infectious organism (also known as pathogen)
develops resistance to one or more drugs that are commonly used in treatment [36]. In
this paper we focus our attention on Mycobacterium tuberculosis, the etiological agent of
tuberculosis, which is the largest infectious killer in the world today, responsible for over 10
million new cases and 2 million deaths every year [37].
The development of resistance to common drugs used in treatment is a serious public
health threat, not only in low and middle-income countries, but also in high-income countries
where it is particularly problematic in hospital settings [40]. It is estimated that, without the
urgent development of novel antimicrobial drugs, the total mortality due to drug resistance
will exceed 10 million people a year by 2050, a number exceeding the annual mortality due
to cancer today [35].
Existing models for predicting drug resistance from whole-genome sequence (WGS) data
broadly fall into two classes. The first, which we refer to as “catalogue methods,” involves
testing the WGS data of an isolate for the presence of point mutations (typically single-
nucleotide polymorphisms, or SNPs) associated with known drug resistance. If one or
more such mutations is identified, the isolate is declared to be resistant [46, 14, 4, 21, 15].
While these methods tend to be easy to understand and apply, they often suffer from
poor predictive accuracy [43], especially in identifying novel drug resistance mechanisms or
screening resistance to untested or rarely-used drugs.
The second class, which we will refer to as “machine learning methods”, seeks to infer
the drug resistance of an isolate by training complex models directly on WGS and drug
susceptibility test (DST) data [48, 11, 2]. Such methods tend to result in highly accurate
predictions at the cost of flexibility and interpretability - specifically, they typically do not
provide any insights into the drug resistance mechanisms involved and often do not impose
explicit limits on the predictive model’s complexity. Learning approaches based on deep
neural networks are one such example.
In this paper we propose a novel method, based on the group testing problem and
Boolean compressed sensing (CS), for the prediction of drug resistance. Compressed sensing
is a mathematical technique for sparse signal recovery from under-determined systems of
linear equations [16], and has been successfully applied in many application areas including
digital signal processing [13, 12], MRI imaging [26], radar detection [19], and computational
uncertainty quantification [29, 9]. Under a sparsity assumption on the unknown signal vector,
it has been shown that CS techniques enable recovery from far fewer measurements than
required by the Nyquist-Shannon sampling theorem [5]. Boolean CS is a slight modification
of the CS problem, replacing the matrix vector product with a Boolean OR operator [28],
and has been successfully applied to areas such as group testing for infection [3, 1].
Our approach combines some of the flexibility and interpretability of catalogue methods
with the accuracy of machine learning methods – specifically, this method is capable of
recovering interpretable rules for predicting drug resistance that both result in a high
classification accuracy as well as provide insights into the mechanisms of drug resistance.
We show that our methods perform comparably to standard machine learning methods on
Mycobacterium tuberculosis in terms of predicting first-line drug resistance, while accurately
recovering many of the known mechanisms of drug resistance, and identifying some potentially
novel ones.
H. Zabeti, N. Dexter, A.H. Safari, N. Sedaghat, M. Libbrecht, and L. Chindelevitch 2:3
2 Methods
Our proposed method is based on the rule-based classification technique introduced in
[28], wherein group testing and Boolean CS are combined to determine subsets of infected
individuals from large populations. In that setting the linear system encodes the infection
status of the population through testing, and the solution, obtained from a suitable decoder,
is a {0, 1}-valued vector representing the infection status of the individuals [6]. Since the
infected group is assumed to be small, the solution vector is sparse and can be recovered
using relatively few measurements with Boolean CS. The result of solving the Boolean CS
problem can then be interpreted as a sparse set of rules for determining infections and used
for classification on unseen data.
We present our methodology as follows. Section 2.1 introduces the group testing problem,
and discusses how group testing can be combined with compressed sensing to deliver an
interpretable predictive model. Section 2.2 introduces modifications to the standard setting
to produce an accurate and flexible classifier, which can be tuned for specific evaluation
metrics and tasks. Section 2.3 describes the tuning process for providing the desired trade-off
between sensitivity and specificity in our model’s predictions. Finally, Section 2.4 describes
an approximation of the AUROC (area under receiver operating characteristic curve), a
standard metric in machine learning, that is valid for evaluating the proposed approach.
2.1 Group testing and Boolean compressed sensing
We frame the problem of predicting drug resistance given sequence data as a group testing
problem, originally introduced in [10]. This approach for detecting defective members of a
set, was motivated by the need to screen large populations for syphilis while drafting citizens
into military service for the United States during the World War II. The screening, performed
by testing blood samples, was costly due to the low numbers of infected individuals. To make
the screening more efficient, Dorfman suggested pooling blood samples into specific groups
and testing the groups instead. A positive result for the group would imply the presence of
at least one infected member. The problem then becomes to find the subset of individuals
whose infected status would explain all of the positive results without invalidating any of the
negative ones. By carefully selecting the groups, the total number of required tests m can be
drastically reduced, i.e. if n is the population size, it is possible to achieve m n.
Mathematically, a group testing problem with m tests can be described in terms of a
Boolean matrix A ∈ {0, 1}m×n, where Aij indicates the membership status of subject j in
the i-th test group, and a Boolean vector y ∈ {0, 1}m, where yi represents the test result of
the i-th group. If w ∈ {0, 1}n is a Boolean vector, with wj representing the infection status
of the j-th individual, then the result of all m tests will satisfy
y = A ∨ w, (1)




Ai,j ∧ wj ∀ 1 ≤ i ≤ m.
If the vector w satisfying equation (1) is assumed to be sparse (i.e. there are few infected
individuals), the problem of finding w is an instance of the sparse Boolean vector recovery
problem:
min ‖w‖0 subject to y = A ∨ w, (2)
where ‖w‖0 is the number of non-zero entries in the vector w.
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Due to the non-convexity of the `0-norm and the nonlinearity of the Boolean matrix
product, the combinatorial optimization problem (2) is well-known to be NP-hard, see, e.g.,
[16, Section 2.3] or [33]. In [27] a relaxation of (2) via linear programming is proposed, with
the `0-norm replaced by the `1-norm (much like in basis pursuit for standard compressed
sensing), and with the nonlinear Boolean matrix product also replaced with two closely related









where P = {i : yi = 1} and Z = {i : yi = 0} are the sets of groups that test positive and
negative, respectively. However, this problem is also NP-hard, but can be made tractable
for linear programming by relaxing the Boolean constraint on w in (3) to 0 ≤ wj ≤ 1 for all
j ∈ {1, . . . , n}.
[28] extended this idea for interpretable rule-based classification, meanwhile proving
recovery guarantees for the relaxed problem. Because the Boolean CS problem is based on
Boolean algebra, the conditions on the Boolean measurement matrices A that guarantee
exact recovery of K-sparse vectors via linear programming are quite different from those
of standard CS. Specifically, these guarantees require the definition of K-disjunct matrices,
i.e., matrices A for which all unions of their columns of size K do not contain any other
columns of the original matrix. Constructions exist for matrices with O(K2 log(n)) rows
which satisfy this property. We also note that by introducing an approximate disjunctness





possible K-subsets of the
columns satisfy the disjunctness condition, it was shown in [30] that there exist constructions
of measurement matrices A which allow for recovery from O(K3/2
√
log(n/ε)) rows.
In the standard setting for uniform recovery results for CS, the measurement matrices A
are subgaussian random matrices, i.e., having entries Ai,j drawn independently according
to a subgaussian distribution. Examples include m× n matrices consisting of Rademacher
or Gaussian random variables, for which uniform recovery of K-sparse vectors via `1-
minimization has been shown under the condition m is O(K log(n/K)), see, e.g. [16, Chapter
9] for more details. While subgaussian matrices have been shown to possess the most
desirable recovery guarantees, they are not always applicable for every measurement scheme,
in particular the one considered here.
In this work, we only consider the Boolean constrained problem, i.e. w ∈ {0, 1}n, though
we adopt the slack variables and regularization proposed by [28] to trade off between the
sparsity and the discrepancy with the test results of the relaxed problem. With these








s.t. w ∈ {0, 1}n (4b)
0 ≤ ξi ≤ 1, i ∈ P (4c)
0 ≤ ξi, i ∈ Z (4d)
APw + ξP ≥ 1 (4e)
AZw − ξZ = 0, (4f)
where λ > 0 is a regularization parameter. This Boolean constrained problem formulation
can be solved via integer linear programming (ILP) techniques, see, e.g., [28].
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2.1.1 Generalization to other contexts
The solution to the ILP (4) can be seen as an interpretable rule-based classifier in contexts
beyond standard group testing. Given a rule for forming the matrix A, encoding binary
attributes of a set of objects through multiple measurements or tests, and test data y, the
general problem is to derive a Boolean disjunction that best classifies previously unseen objects
from their features. In such a general setting, a context-specific technique for dichotomizing
features may be needed [41]. However, in the case of drug resistance prediction, our features
are the presence or absence of specific single-nucleotide polymorphisms (SNPs), and therefore
no dichotomization is needed.
From now on, we assume that we have a binary labeled dataset D={(x1, y1),. . . ,(xm, ym)},
where the xi ∈ X := {0, 1}n are n-dimensional binary feature vectors and the yi ∈ {0, 1} are
the binary labels. The feature matrix A is defined via Ai,j = (xi)j (the j-th component of
the i-th feature vector). If ŵ is the solution of ILP (4) for this feature matrix and the label
vector y = (yi)mi=1, we define the classifier ĉ : X → {0, 1} as follows:
ĉ(x) = x ∨ ŵ. (5)
2.2 Our approach
The formulation of the ILP (4) is designed to provide a trade-off between the sparsity of
a disjunctive rule and the total slack, a quantity that resembles (but does not equal) the
training error. Unmodified, these conditions are not ideal for machine learning tasks: i)
they do not allow for accurate expression of this error, and ii) they lack the ability to assign
different weights to different components of the error. Such a weighting can play a large
role in settings where the data is highly unbalanced, or when the cost of a false positive
differs greatly from that of a false negative. We now describe an approach that provides
more flexibility in the training process and performs better on specific tasks such as ours.
Recall that the regularization parameter λ in equation (4) provides control over the
trade-off between the total slack and the sparsity of the solution. It is straightforward to
generalize this term to provide useful information about the classifier’s false positive and
false negative rates. To obtain this information, we modify the ILP (4) in two ways.
For clarity, in the following section we assume that ĉ is a binary classifier trained on a
sample y with corresponding Boolean feature matrix A. In addition, unless otherwise stated,
we refer to the misclassification of a training sample as a false negative if it has label 1 (is
in P), and as a false positive if it has label 0 (is in Z). For instance, in the case of drug
resistance, a false negative would mean that we incorrectly predict a drug-resistant isolate
as sensitive, while a false positive would mean that we predict a drug-sensitive isolate as
resistant.
First, note that in ILP (4), ξP corresponds to the training error of ĉ on the positively
labeled subset of the data, while ξZ does not correspond to its training error on the negatively
labeled subset. This follows from the fact that A is a binary matrix and w is a binary vector,
so ξP is also a binary vector, with∑
i∈P
ξi = 1T ξP = FN, (6)
the number of false negatives. On the other hand, to obtain the number of false positives
(FP) we need to modify the constraints (4d) and (4f) by setting
ξi ∈ {0, 1}, i ∈ Z (7)
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and replacing AZw − ξZ = 0 with the inequalities:
AZw − ξZ ≥ 0, (8a)
αiξi −Aiw ≥ 0 ∀ i ∈ Z, (8b)
where αi =
∑n
j=1 Ai,j and Ai represent ith row of A. Note that the motivation behind this
replacement is to count the number of non-zero elements of AZw by ξZ . Therefore, we
can observer that eq.(8a) ensure that ξi = 0 if Aiw = 0 and eq.(8b) ensures that ξi = 1
if Aiw > 0. However, eq.(8a) can be eliminated in those settings where the ξZ enter the
objective function to be minimized with a positive coefficient. We will see similar situations
in the following section.
After these modifications, we obtain∑
i∈Z
ξi = 1T ξZ = FP. (9)
To provide the desired flexibility, we further split the regularization term into two terms



















s.t. w ∈ {0, 1}n
0 ≤ ξi ≤ 1, i ∈ P
ξi ∈ {0, 1}, i ∈ Z
APw + ξP ≥ 1
αiξi −Aiw ≥ 0 ∀ i ∈ Z
(11)
In this new formulation, λP and λZ control the trade-off between the false positives and the
false negatives, and jointly influence the sparsity of the rule. This formulation can be further
tailored to optimize specific evaluation metrics. In the following section we demonstrate this
for sensitivity and specificity, as an example.
2.3 Optimizing sensitivity and specificity
Since the ILP formulation in (11) provides us with direct access to the two components of
the training error, we may modify the classifier to optimize a specific evaluation metric. For
instance, assume that we would like to train the classifier ĉ to maximize the sensitivity at a
given specificity threshold t̄. First, recall that
Specificity = TNTN+FP = 1−
FP
N , (12)
Sensitivity = TPTP+FN = 1−
FN
P . (13)
From equation (10), equation (12) and the definition of Z, we get the constraint
t̄ ≤ 1− 1
T ξZ
|Z|
⇐⇒ 1T ξZ ≤ (1− t̄)|Z|. (14)
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Our objective is to maximize sensitivity, which is equivalent to minimizing
∑
i∈P ξi by








s.t. w ∈ {0, 1}n
0 ≤ ξi ≤ 1, i ∈ P
ξi ∈ {0, 1}, i ∈ Z
APw + ξP ≥ 1
αiξi −Aiw ≥ 0 ∀ i ∈ Z
1T ξZ ≤ (1− t̄)|Z|.
(15)
The maximum specificity at given sensitivity can be found analogously.
2.4 Approximating the AUROC
In this section we compute an analog of the AUROC1 of our classifier given a limit on rule
size. Recall that the ROC is a plot demonstrating the performance of a score-producing
classifier at different score thresholds, created by plotting the true positive rate (TPR) against
the false positive rate (FPR). However, since the rule-based classifier produced by ILP (11) is
a discrete classifier, it cannot produce a ROC curve in the usual way. To create a ROC curve
for this classifier, we compute the true positive rate (TPR) for different values of the false
positive rate (FPR). In addition, we set a limit on the rule size (sparsity) of the classifier.
More precisely, we create the ROC curve by incrementally changing the FPR and
computing the optimum value of the TPR. To do so, we put varying upper bounds on the
FPR and proceed analogously to the previous section. For instance, assume that we would
like to get the best TPR value when the FPR is at most t̂, where 0 ≤ t̂ ≤ 1, meaning that
FPR = FPN ≤ t̂. (16)
From equations (10), (16) and the definition of Z we get
1T ξZ
|Z|
≤ t̂ ⇐⇒ 1T ξZ ≤ t̂|Z|. (17)
Assuming further that the limit on rule size is equal to ŝ, we have the following constraint:
1Tw ≤ ŝ. (18)
1 the Area Under the Receiver Operating Characteristic Curve
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s.t. w ∈ {0, 1}n
0 ≤ ξi ≤ 1, i ∈ P
ξi ∈ {0, 1}, i ∈ Z
APw + ξP ≥ 1
αiξi −Aiw ≥ 0 ∀ i ∈ Z
1Tw ≤ ŝ
1T ξZ ≤ t̂|Z|.
(19)
We utilize the CPLEX optimizer [20] to solve the ILP in (19).
3 Implementation
All the methods in this paper are implemented in the Python programming language. We
use a Scikit-learn [38] implementation for the machine learning models and the CPLEX
optimizer version 12.10.0 [20], together with its Python API, for our method.
3.1 Data
To obtain a dataset to train and evaluate our method on, we combine data from the Pathosys-
tems Resource Integration Center (PATRIC)[47] and the Relational Sequencing TB Data
Platform (ReSeqTB)[45]. This results in 8000 isolates together with their resistant/sus-
ceptible status (label) for seven drugs, including five first-line drugs (rifampicin, isoniazid,
pyrazinamide, ethambutol, and streptomycin) and two second-line drugs (kanamycin and
ofloxacin) [34, 8]. The short-read whole genome sequences of these 8000 isolates are down-
loaded from the European Nucleotide Archive [23] and the Sequence Read Archive [24].
The accession numbers used to obtain the data in our study were: ERP[000192, 006989,
008667, 010209, 013054, 000520], PRJEB[10385, 10950, 14199, 2358, 2794, 5162, 9680],
PRJNA[183624, 235615, 296471], and SRP[018402, 051584, 061066].
In order to map the raw sequence data to the reference genome, we use a method similar
to that used in previous work [7, 8]. We use the BWA software [25], specifically, the bwa-mem
program. We then call the single-nucleotide polymorphisms (SNPs) of each isolate with two
different pipelines, SAMtools [18] and GATK [39], and take the intersection of their calls to
ensure reliability. The final dataset, which includes the position as well as the reference and
alternative allele for each SNP [8], is used as the input to our classifier.
Starting from this input we create a binary feature matrix, where each row represents an
isolate and each column indicates the presence or absence of a particular SNP. For each drug,
we group all the SNPs with identical presence/absence patterns into a single column, since at
most one SNP in a group would ever be selected to be part of a rule. The number of labeled
and resistant isolates and of SNPs and SNP groups for each drug is stated in Table 1.
3.2 Train-Test split
To evaluate our classifier we use a stratified train-test split, where the training set contains
80% and the testing set contains 20% of data.
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Table 1 Summary of number of isolates in our data.
Drug Number of isolates Number of resistant isolates Number of SNPs Number of SNP groups
Ethambutol 6,096 1,407 666,349 55,164
Isoniazid 7,734 3,445 666,349 65,090
Kanamycin 2,436 697 666,349 21,513
Ofloxacin 2,911 800 666,349 23,905
Pyrazinamide 3,858 754 666,349 33,942
Rifampicin 7,715 2,968 666,349 65,379
Streptomycin 5,125 2,104 666,349 45,037
3.3 AUROC comparison
The AUROC of our model was computed for two purposes: first, to investigate the effect of
the classifier’s sparsity (rule size) on its performance, and second, to compare this performance
to that of other machine learning methods. We calculated the AUROC of classifiers with
various limits on rule size, selected from {1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200}. For
each rule size, we use the formulation in subsection 2.4, increasing the FPR upper bound
from 0 to 1 in increments of 0.1. We then train a classifier by using the ILP (19), and
compute the effective FPR and TPR. Lastly, we create the ROC curve by plotting the TPRs
against the FPRs, and compute the AUROC.
To compare the performance of our model with other machine learning models, we also
compute the AUROC of the Random Forest (RF) and `1-regularized Logistic Regression
(LR) models. For these models, we first perform hyper-parameter tuning using grid search
with three-fold cross validation, and then select the model with the highest AUROC.
3.4 Sensitivity at a fixed specificity
As another evaluation criteria we compute the sensitivity of our model at a desired specificity
level (i.e. β% specificity). To do so, we use the ILP (15). In this formulation, the λP
parameter can be tuned to provide the desired trade-off between the sparsity of the classifier
(i.e., rule size) and the number of false negatives. However, in order to make a consistent
comparison between the trained models for different drugs, we set a specific limit on rule
size and use ILP (19) with the last constraint replaced by the last constraint of ILP (15), i.e.
with (17) replaced with (14).
4 Results
Evaluating the performance of an interpretable predictive model can be challenging. While
most evaluation methods focus on predictive accuracy, it is essential to assess the model’s
interpretability. Even though there is no consensus on the definition of interpretability, the
“Predictive, Descriptive, Relevant” (PDR) framework introduced by [32] provides general
insights into interpretable models, by emphasizing the balance between these characteristics.
In this section, we use the PDR framework to evaluate our models in the following ways.
First, in Section 4.1, we assess our method’s predictive accuracy by comparing it with RF
and LR. At this step we do not have any specific restriction on the rule size, and we report
the best AUROC that our model can achieve based on the settings in Section 3.3.
Second, in Section 4.2, we compare the AUROC produced by our method for different
limits on rule size. This comparison between the method at different parameter values helps
us evaluate its ability to produce a simple model (i.e. a model with a fairly small rule size)
with a high AUROC. The simpler models are easier to understand for human users. In
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Figure 1 Comparison between the test AUROC of our rule-based model (with no limit imposed
on the rule size), `1-regularized logistic regression and Random Forest.
this paper, we define the descriptiveness of a model by its simplicity (its rule size, i.e., the
number of SNPs needed to define it). In addition, we evaluate our method’s sensitivity by
comparing it with LR and RF. To do so, we compute and compare the sensitivity of these
three models at a specificity near 90%. More specifically, this comparison uses the specificity
level achieved by the rule-based model that is closest to 90% (in practice, this is always
between 88% and 92% for this dataset), since the rule-based model does not achieve every
possible specificity level when given a limit on rule size. For this evaluation, we limit model
complexity by setting a limit of 20 on the rule size.
Finally, in Section 4.3, we assess the relevance of the model produced by our method
by observing the fraction of SNPs used by the model that are located in genes previously
reported to be associated with drug resistance. Note that, unlike the approach in [48], we do
not limit the genes a priori to those with known associations with drug resistance.
4.1 Our models produce competitive AUROCs
Figure 1 illustrates the results of comparing our model to LR and RF. In this figure, we
can see that LR provides a higher AUROC for all 7 drugs, but our model produces slightly
higher AUROCs than RF for 3 of the drugs, identical AUROCs for 2 other drugs and slightly
lower ones for the remaining 2.
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Table 2 Comparison between AUROCs of models produced by our method with different rule
size limits. We observe that even small rule sizes produce models with a high AUROC.
Drug Rule size ≤ 10 Rule size ≤ 20 Rule size ≤ 30 Rule size ≤ 40 Max AUROC
Ethambutol 0.86 0.86 0.85 0.86 0.87
Isoniazid 0.88 0.89 0.90 0.91 0.92
Kanamycin 0.88 0.89 0.89 0.88 0.89
Ofloxacin 0.90 0.87 0.90 0.88 0.90
Pyrazinamide 0.88 0.88 0.88 0.89 0.89
Rifampicin 0.90 0.92 0.92 0.93 0.93
Streptomycin 0.84 0.86 0.85 0.87 0.88
4.2 Our approach is able to produce simple models with high AUROC
Figure 2 demonstrates the change in AUROC as we increase the limit on the rule size. Our
results show that as the limit on the rule size increases, we get higher AUROC on the training
set. However, on the test set, we see that the AUROC increases more slowly after a rule size
limit of 10, and eventually starts to decrease.
As shown in Figure 2 and Table 2, the AUROC does not increase significantly beyond
a rule size limit of 10. Thus, our method is capable of producing models with a rule sizes
small enough to keep the model simple yet keep the AUROC within 1% of the maximum.
Table 3 shows the same trend for the `1-regularized logistic regression. We see that, at
the low rule-size limits (such as 10 and 20), our approach produces a comparable performance
to that of `1-regularized logistic regression, while it is slightly worse for larger rule-size limits.
At the same time, as we show in Figures 4a and 4b below, our approach results in the recovery
of a lot more genes known to be associated with drug resistance than logistic regression.
4.3 Our model uses genes previously associated to drug resistance
Our results show that the models produced by our method contains many SNPs in genes
previously associated with drug resistance in Mycobacterium tuberculosis. Due to the large
size of SNP groups (SNPs in perfect linkage disequilibrium), the causality of specific SNPs
remains difficult to determine. However, many of the genes known to be relevant to resistance
mechanisms appear among the possible variants that are pointed to by the selected groups
of duplicated SNPs.
In Figure 4a we show the number of SNPs within different classes of genes found by our
approach with rule size ≤ 20 and specificity ≥ 90%, where each gene is classified according to
whether it has a known association to drug resistance (“known”) or not (“unknown”), with
Table 3 Comparison between AUROCs of models produced by `1-regularized logistic regression
with different numbers of non-zero regression coefficients.
Drug Non-zero coef. ≤ 10 Non-zero coef. ≤ 20 Non-zero coef. ≤ 30 Non-zero coef. ≤ 40 Max AUROC
Ethambutol 0.87 0.87 0.88 0.89 0.91
Isoniazid 0.90 0.91 0.92 0.93 0.96
Kanamycin 0.90 0.91 0.91 0.92 0.92
Ofloxacin 0.86 0.90 0.94 0.94 0.94
Pyrazinamide 0.81 0.87 0.89 0.89 0.90
Rifampicin 0.92 0.92 0.94 0.94 0.97
Streptomycin 0.88 0.88 0.89 0.90 0.92
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Figure 2 Test AUROC for models trained on each drug with various rule size limits. Beyond a
certain rule size, which varies with the drug, the AUROC of the predictive model no longer improves.
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Figure 3 Comparison between the sensitivity of our rule-based method with the rule size limit
set to 20, `1-Logistic regression and Random Forest at around 90% specificity on the testing data.
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(a) (b)
Figure 4 (a) The number of SNPs in genes with known association to drug resistance, genes
without such an association, and intergenic regions, in our models with at most 20 SNPs and a
specificity of ≥ 90%. (b) The same numbers for `1-Logistic regression models with as close as
possible to 20 non-zero regression coefficients.
an additional class for SNPs in intergenic regions. We show these numbers for `1-Logistic
regression models with as close as possible to 20 non-zero regression coefficients in Figure 4b.
A comparison between these figures suggests that when both approaches are restricted to a
small number of features, our approach detects more relevant SNPs than `1-logistic regression.
The list of “known” genes, selected through a data-driven and consensus-driven process by a
panel of experts, is the one in [31], containing 183 out of over 4,000 M. tuberculosis genes.
We note that in both cases, a group of SNPs in perfect linkage disequilibrium was coded as
“known” if at least one of the SNPs was contained in a known gene, “intergenic” if none of
them appeared in a gene, and as “unknown” otherwise.
4.4 Running time
We run our code on a cluster node with 2 CPU sockets, each with an 8-core 2.60 GHz Intel
Xeon E5-2640 v3 with 32 threads. The training of a single model with fixed hyper-parameters
takes between 1 and 8 minutes. This suggests that once a suitable value is chosen for the
hyper-parameters, the optimization used to determine the optimal rule can be performed
efficiently. Overall, producing the ROC curve for each drug takes between 3 and 18 hours,
depending on the number of labeled isolates available for each drug.
5 Conclusion
In this paper, we introduced a new approach for creating rule-based classifiers. Our method
utilizes the group testing problem and Boolean compressed sensing. It can produce inter-
pretable, highly accurate, flexible classifiers which can be optimized for particular evaluation
metrics.
We used our method to produce classifiers for predicting drug resistance in Mycobacterium
tuberculosis. The classifiers’ predictive accuracy was tested on a variety of antibiotics
commonly used for treating tuberculosis, including five first-line and two second-line drugs.
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We show that our method could produce classifiers with a high AUROC, slightly less than that
of unrestricted `1-Logistic regression, and comparable to Random Forest, as well as `1-Logistic
regression restricted to a comparably small number of selected features for interpretability.
In addition, we show that our method is capable of producing accurate models with a rule
size small enough to keep the model understandable for human users. Finally, we show that
our approach can provide useful insights into its input data - in this case, it could help
identify genes associated with drug resistance.
We note that the presence of SNPs with identical presence/absence patterns, which would
be referred to as being in perfect linkage disequilibrium (LD) in genetics [42], is common
in bacteria such as Mycobacterium tuberculosis whose evolution is primarily clonal [17].
For this reason, while the grouping of such SNPs together substantially greatly simplifies
the computational task at hand, it is challenging to ascertain the exact representative of
each group that should be selected to determine the drug resistance status of an isolate.
Determining this representative would likely require larger sample sizes or a built-in prior
knowledge of the functional effects of individual SNPs.
We also note that the genes we define as having a known association to drug resistance
are not specific to the drug being tested, i.e. some of them may have been found to be
associated with the resistance to a drug other than the one being predicted. This is to be
expected, however, as the distinct resistance mechanisms are generally less numerous than
antibiotics [44]. It will be interesting to see whether methods such as ours are able to detect
specific, for instance, by testing it on data for newly developed antibiotics such as bedaquiline
and delamanid [22].
Our goal in this paper was to introduce a novel method for producing interpretable models
and explore its accuracy, descriptive ability, and relevance in detecting drug resistance in
Mycobacterium tuberculosis isolates. In this study, the focus was mostly on the predictive
accuracy, and we will explore the similarities and differences between our model and other
interpretable techniques (both model-based and post-hoc ones) in future work.
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